![PDF) Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment PDF) Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment](https://i1.rgstatic.net/publication/324760355_Pharmacokinetics_Safety_and_Tolerability_of_Oral_Semaglutide_in_Subjects_With_Hepatic_Impairment/links/5ae1224e458515c60f65f61f/largepreview.png)
PDF) Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
![Jesper LAU | Vice President | PhD | Novo Nordisk, Copenhagen | Diabetes protein and peptide chemistry Jesper LAU | Vice President | PhD | Novo Nordisk, Copenhagen | Diabetes protein and peptide chemistry](https://i1.rgstatic.net/ii/profile.image/272496222011408-1441979570981_Q512/Jesper_Lau.jpg)
Jesper LAU | Vice President | PhD | Novo Nordisk, Copenhagen | Diabetes protein and peptide chemistry
![Thomas KRUSE | Principal scientist | Doctor of Philosophy | Novo Nordisk, Copenhagen | propep2 Novo Nordisk Thomas KRUSE | Principal scientist | Doctor of Philosophy | Novo Nordisk, Copenhagen | propep2 Novo Nordisk](https://www.researchgate.net/profile/Sanford_Asher/publication/230094100/figure/tbl1/AS:668209128685596@1536324879899/Crystal-data-and-experimental-details_Q320.jpg)
Thomas KRUSE | Principal scientist | Doctor of Philosophy | Novo Nordisk, Copenhagen | propep2 Novo Nordisk
![Bentham Science | Publisher of excellence for all Biomedical, Medical and Pharmaceutical Decision Makers Bentham Science | Publisher of excellence for all Biomedical, Medical and Pharmaceutical Decision Makers](https://www.eurekaselect.com/images/graphical-abstract/lddd/17/5/014.jpg)